bodisen biotech inc (BODI) Snapshot

Bodisen Biotech Inc. reported consolidated earnings results for the year ended December 31, 2012. For the period, the company reported revenue of $8,055,958 compared with $7,684,778 for the same period last year. Loss from operations was $13,531,194 compared with $2,260,830 for the same period last year. Net loss was $16,369,802 or $0.76 diluted per share compared with $2,310,372 or $0.11 diluted per share for the same period last year. Net cash used in operating activities was $2,069,399 compared with $2,816,911 for the same period last year. Acquisition of property and equipment was $16,005 compared with $12,686 for the same period last year. The increase in revenue is primarily attributable to increased demand from customers for new fertilizer.

On 04/01/2013, Bodisen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Bodisen Biotech Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2012. For the quarter, the company reported revenues of $3,320,635, loss from operations of $192,794, net loss of $210,804 or $0.01 basic and diluted share compared to revenues of $1,781,006, loss from operations of $813,641, net loss of $792,607 or $0.04 basic and diluted share for the same quarter year ago. For the nine months, the company reported revenues of $5,830,158, loss from operations of $2,263,006, net loss of $2,279,132 or $0.11 basic and diluted share compared to revenues of $4,222,293, loss from operations of $1,173,189, net loss of $1,119,530 or $0.05 basic and diluted share for the same period year ago. Net cash used in operating activities was $2,005,197 compared to the $2,830,406 for the same period year ago. Acquisition of property and equipment was $15,985 against $538 a year ago. The increase in revenue is primarily attributable to its wholly-owned subsidiary; Bodisen Xinjiang started to generate revenue from the sale of fertilizer in the amount of $1,638,363 during the quarter ended September 30, 2012.